RMA-Red

Amendment Statement of Principles

concerning

SARCOIDOSIS
(Balance of Probabilities)

(No. 14 of 2019)

The Repatriation Medical Authority determines the following Amendment Statement of Principles under subsections 196B(3) and (8) of the Veterans' Entitlements Act 1986.

 

Dated                                            21 December 2018

 

 

 

 

 

The Common Seal of the
Repatriation Medical Authority
was affixed to this instrument
at the direction of:

 

 

Professor Nicholas Saunders AO

Chairperson

 

 

 

Contents

1 Name

2 Commencement

3 Authority

4 Amendment

 


1               Name

This is the Amendment Statement of Principles concerning sarcoidosis (Balance of Probabilities) (No. 14 of 2019).

2               Commencement

              This instrument commences on 28 January 2019.

3               Authority

This instrument is made under subsections 196B(3) and (8) of the Veterans' Entitlements Act 1986.

4               Amendment

The Statement of Principles concerning sarcoidosis (Balance of Probabilities) (No. 60 of 2016) (Federal Register of Legislation No. F2016L01143) is amended in the following manner:

Section

Amendment

9(1)

Replace the existing factor in subsection 9(1) with the following:

being treated with a drug from a class of drugs from the specified list of drugs within the five years before the clinical onset of sarcoidosis;

Note: specified list of drugs is defined in the Schedule 1 - Dictionary.

 

9(3)

Replace the existing factor in subsection 9(3) with the following:

being treated with a drug from a class of drugs from the specified list of drugs within the five years before the clinical worsening of sarcoidosis;

Note: specified list of drugs is defined in the Schedule 1 - Dictionary.

 

Schedule 1 – Dictionary

Insert the following definition of "specified list of drugs" in alphabetical order:

specified list of drugs means:

(a)          BRAF/MEK inhibitors, including, but not limited to, vemurafenib, dabrafenib and trametinib;

(b)          immune checkpoint inhibitors, including, but not limited to, ipilimumab, pembrolizumab and nivolumab; or

(c)          interferons.